Advertisement

Advertisement
Gynecologic Cancers

Progression-Free Survival Benefit Confirmed With Triplet Combination in BRCA Wild-Type, HRD-Positive Ovarian Cancer

The combination of immunotherapy, targeted therapy, and chemotherapy could be the new standard first-line treatment of patients with high-grade, advanced...

Lung Cancer

T-DXd in HER2-Overexpressing Unresectable or Metastatic NSCLC

As reported in The Lancet Oncology by Egbert F. Smit, MD, and colleagues, primary analysis in the HER2-overexpressing unresectable or metastatic non–small cell cancer...

Thyroid Cancer

New Findings Suggest No Correlation Between GLP-1 Receptor Agonists and Thyroid Cancer Risk

Glucagon-like peptide (GLP)-1 receptor agonists may not be associated with an increased risk of thyroid cancer, according to a recent study...


Advertisement
Solid Tumors

Cabozantinib in Advanced Adrenocortical Carcinoma

In a single-center phase II trial reported in The Lancet Oncology, Campbell et al found that cabozantinib monotherapy showed activity in adult patients...

Lung Cancer

NSCLC: Neoadjuvant Chemoimmunotherapy vs Neoadjuvant Chemotherapy

In a systematic review and meta-analysis reported in JAMA Oncology, Sorin et al found that neoadjuvant chemoimmunotherapy was associated with better...

Advertisement
Advertisement




Sponsored Content


Breast Cancer

Geoffrey J. Lindeman, MBBS, PhD, on Breast Cancer: Venetoclax and Fulvestrant in ER-Positive, HER2-Negative Disease

Gynecologic Cancers

OUTBACK Trial: No Survival Benefit With Adjuvant Chemotherapy After Standard Chemoradiation for Locally Advanced Cervical Cancer

Cervical cancer is the fourth most common cancer in women worldwide, and the leading cause of cancer-related death among women in Eastern, Western, Middle, and Southern Africa. Globally, in 2018, approximately 570,000 women were diagnosed with cervical cancer, and 311,000 women died. In the United...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Leukemia
Immunotherapy

Bijal D. Shah, MD, on CLL: CAR T-Cell Therapy With Brexucabtagene Autoleucel

Breast Cancer

Does Vitamin D Supplementation Improve Prognosis for Patients With Breast Cancer?

A research team has found that sufficient vitamin D levels at the time of diagnosis may be associated with improved outcomes among people with breast cancer. These findings were presented by Yao et al during the 2021 ASCO Annual Meeting (Abstract 10510). These findings are based on Kaiser...

Gynecologic Cancers
Cost of Care

Nearly Half of Surveyed Patients With Gynecologic Cancer Report Experiencing Financial Toxicity

In a new study designed to provide a more comprehensive picture of how a diverse cohort of patients with gynecologic cancer are affected by financial distress, nearly half reported financial toxicity, which was associated with economic cost-coping strategies. These findings were reported by Esselen ...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Multiple Myeloma

Taiga Nishihori, MD, on Multiple Myeloma: Maintenance Ixazomib After Transplant

Bladder Cancer
Immunotherapy

CheckMate 274: Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma

As reported in The New England Journal of Medicine by Dean F. Bajorin, MD, and colleagues, an interim analysis of the phase III CheckMate 274 trial has shown improved disease-free survival with adjuvant nivolumab vs placebo among all patients with high-risk muscle-invasive urothelial carcinoma who...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...

Twitter